Recro Pharma, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Geraldine Henwood
- Full Time Employees
- 185
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 490 Lapp Rd Malvern PA United States of America 19341
- IPO Date
- Mar 7, 2014
- CIK
- 0001588972
- Website
- recrocdmo.com
- Similar Companies
- Business
- Recro Pharma, Inc. (REPH), now operating as Societal CDMO, Inc., functions as a contract development and manufacturing organization (CDMO) specializing in small molecule therapeutics; it provides end-to-end services from pre-Investigational New Drug development through commercial manufacturing and packaging for diverse dosage forms including oral solid doses, sterile injectables, oral liquids, tablets, topicals, liquid/powder-filled capsules, ophthalmic droppers, liposomes, and nano/microparticles; core capabilities encompass therapeutic development, regulatory support, aseptic fill/finish, lyophilization, clinical trial services such as sachet and blister packaging, logistics, handling of DEA-controlled substances, and modified-release formulations. Founded in 2007 and headquartered in Exton, Pennsylvania, with primary manufacturing facilities totaling 145,000 square feet in Gainesville, Georgia, and San Diego, California, the company serves global pharmaceutical clients across clinical and commercial stages, targeting complex formulation challenges in the U.S. and international markets. In March 2022, Recro Pharma rebranded to Societal CDMO, Inc. (NASDAQ: SCTL) to reflect its evolution following the 2021 acquisition of IriSys, Inc. for approximately $50 million, which established a bi-coastal footprint and expanded offerings beyond oral solids to sterile injectables and advanced dosage forms; in April 2024, CoreRx, Inc. completed its acquisition of Societal CDMO for $1.10 per share in cash totaling around $130 million, integrating it as a wholly-owned subsidiary and delisting its shares from Nasdaq.
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
Recro Reports Inducement Grants For New Staff
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Recro Announces Acquisition of San Diego-based IRISYS, Creating Bi-Coastal, Full Service CDMO
Recro Pharma, Inc. (REPH) CEO David Enloe on Q2 2021 Results - Earnings Call Transcript
Recro Pharma: Q2 Earnings Insights
Recro To Report Financial Results for Second Quarter 2021 on August 9, 2021
Recro Appoints Laura L. Parks, Ph.D.
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Recro Announces Proposed Public Offering of Common Stock
Recro Pharma, Inc. (REPH) CEO David Enloe on Q1 2021 Results - Earnings Call Transcript
Recro Reports First Quarter 2021 Financial Results
Recro to Report Financial Results for First Quarter 2021 on May 6